SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Shoo BA, Kashani-Sabet M. Melanoma arising in African-, Asian-, Latino- and Native-American populations. Semin Cutan Med Surg. 2009; 28: 96-102.
  • 2
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER*Stat Database: Incidence—SEER 9 Registries Research Data, November 2010 submission (1973-2008) (Katrina/Rita Population Adjustment)—Linked to County Attributes; Total US, 1969-2009 Counties; Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2011 [released April 2011, based on the November 2012 submission].
  • 3
    Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009; 129: 16661674.
  • 4
    Bandarchi B, Ma L, Navab R, Seth A, Rasty G. From melanocyte to metastatic malignant melanoma [serial online]. Dermatol Res Pract. 2010; 2010:p ii.
  • 5
    Chang NB, Feng R, Gao Z, Gao W. Skin cancer incidence is highly associated with ultraviolet-B radiation history. Int J Hyg Environ Health. 2010; 213: 359368.
  • 6
    Veierod MB, Adami HO, Lund E, Armstrong BK, Weiderpass E. Sun and solarium exposure and melanoma risk: effects of age, pigmentary characteristics, and nevi. Cancer Epidemiol Biomarkers Prev. 2010; 19: 111120.
  • 7
    Cust AE, Armstrong BK, Goumas C, et al. Sunbed use during adolescence and early adulthood is associated with increased risk of early onset melanoma. Int J Cancer. 2011; 128: 24252435.
  • 8
    Lazovich D, Vogel RI, Berwick M, Weinstock MA, Anderson KE, Warshaw EM. Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev. 2010; 19: 15571568.
  • 9
    Godden D, Brennan PA, Milne J. Update on melanoma: the present position. Br J Oral Maxillofac Surg. 2010; 48: 575578.
  • 10
    Manganoni AM, Zanotti F, Farisoglio C, Feroldi P, Facchetti F, Calzavara-Pinton P. Important risk factors in melanoma from the Dermato-Oncologic Unit of Brescia, Italy [serial online]. Dermatol Online J. 2010; 16: 17.
  • 11
    Santillan AA, Cherpelis BS, Glass LF, Sondak VK. Management of familial melanoma and nonmelanoma skin cancer syndromes. Surg Oncol Clin North Am. 2009; 18: 73-98, viii.
  • 12
    Nagore E, Hueso L, Botella-Estrada R, et al. Smoking, sun exposure, number of nevi and previous neoplasias are risk factors for melanoma in older patients (60 years and over). J Eur Acad Dermatol Venereol. 2010; 24: 5057.
  • 13
    Markovic SN, Geyer SM, Dawkins F, et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer. 2005; 103: 25842589.
  • 14
    Croghan GA, Suman VJ, Maples WJ, et al. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer. 2010; 116: 34633468.
  • 15
    Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D. Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol. 2010; 74: 2739.
  • 16
    Saito A, Saito N, Mol W, et al. Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008; 18: 8594.
  • 17
    Glynn SA, O'Sullivan D, Eustace AJ, Clynes M, O'Donovan N. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells [serial online]. BMC Cancer. 2008; 8: 9.
  • 18
    Minichsdorfer C, Hohenegger M. Autocrine amplification loop in statin-induced apoptosis of human melanoma cells. Br J Pharmacol. 2009; 157: 12781290.
  • 19
    Sora MK, Kruszewski AA, Stoklosa T, et al. Synergistic antiproliferative activity of tumor necrosis factor alpha (TNF-alpha) and lovastatin. Arch Immunol Ther Exp (Warsz). 1994; 42: 269274.
  • 20
    Kidera Y, Tsubaki M, Yamazoe Y, et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway [serial online]. J Exp Clin Cancer Res. 2010; 29: 127.
  • 21
    Spatz ES, Canavan ME, Desai MM. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes. 2009; 2: 4148.
  • 22
    Freeman SR, Drake AL, Heilig LF, et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst. 2006; 98: 15381546.
  • 23
    Bonovas S, Nikolopoulos G, Filioussi K, Peponi E, Bagos P, Sitaras NM. Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. Eur J Epidemiol. 2010; 25: 29-35.
  • 24
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279: 1615-1622.
  • 25
    Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000; 160: 23632368.
  • 26
    Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004; 22: 23882394.
  • 27
    Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004; 90: 635637.
  • 28
    Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998; 19: 61-109.
  • 29
    Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol. 2003; 13: S107-S121.
  • 30
    Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol. 2003; 13: S5-S17.
  • 31
    Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998; 19: 2637.
  • 32
    Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005; 19: 117125.
  • 33
    Duncan RE, El-Sohemy A, Archer MC. Statins and the risk of cancer. JAMA. 2006; 295: 27202722.
  • 34
    Bischoff H, Heller AH. Preclinical and clinical pharmacology of cerivastatin. Am J Cardiol. 1998; 82: 18J-25J.
  • 35
    Davidson MH. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs. 2002; 11: 125141.
  • 36
    Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998; 81: 582587.
  • 37
    Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003; 13: S122-S128.
  • 38
    Jee SH, Lee SY, Chiu HC, Chang CC, Chen TJ. Effects of estrogen and estrogen receptor in normal human melanocytes. Biochem Biophys Res Commun. 1994; 199: 14071412.
  • 39
    Pasco S, Brassart B, Ramont L, Maquart FX, Monboisse JC. Control of melanoma cell invasion by type IV collagen. Cancer Detect Prev. 2005; 29: 260266.
  • 40
    Bonovas S, Sitaras NM. Statins and cancer risk: a confounded association. Gastroenterology. 2009; 137: 740741.
  • 41
    Gentile S, Turco S, Guarino G, et al. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Diabetes Obes Metab. 2000; 2: 355362.
  • 42
    Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus “usual” care in secondary coronary heart disease prevention. The Greek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) study. Curr Med Res Opin. 2002; 18: 220-228.
  • 43
    Arntz HR, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin (±colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol. 2000; 86: 12931298.
  • 44
    Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001; 286: 6470.
  • 45
    Boright AP, Connelly PW, Brunt JH, Morgan K, Hegele RA. Association and linkage of LDLR gene variation with variation in plasma low density lipoprotein cholesterol. J Hum Genet. 1998; 43: 153159.
  • 46
    Serruys PW, de Feyter P, Macaya C, et al. Lescol Intervention Prevention (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 287: 3215-3222.
  • 47
    Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the Fluvastatin Angiographic Restenosis (FLARE) trial. Eur Heart J. 1999; 20: 5869.
  • 48
    Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997; 80: 278286.
  • 49
    Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during 1 year of treatment. Atherosclerosis. 1999; 144: 263270.
  • 50
    Stegmayr BG, Brannstrom M, Bucht S, et al. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scand J Urol Nephrol. 2005; 39: 489497.
  • 51
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333: 1301-1307.
  • 52
    Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Ital Heart J. 2000; 1: 810-820.
  • 53
    Marschner IC, Colquhoun D, Simes RJ, et al. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study LIPID Study Investigators. J Am Coll Cardiol. 2001; 38: 5663.
  • 54
    Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393] [serial online]. BMC Med. 2005; 3: 6.
  • 55
    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389.
  • 56
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335: 1001-1009.
  • 57
    Lipkin SM, Chao EC, Moreno V, et al. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila). 2010; 3: 597603.